Please login to the form below

Not currently logged in
Email:
Password:

MS

This page shows the latest MS news and features for those working in and with pharma, biotech and healthcare.

FDA delays review of Novartis’ MS drug ofatumumab

FDA delays review of Novartis’ MS drug ofatumumab

MS. The antibodies are thought to deplete these B cells, reducing their production of antibodies that attack myelin. ... relapses than Sanofi’s once-daily oral MS drug Aubagio (teriflunomide), reducing the rate by 50.5% and 58.5% respectively.

Latest news

More from news
Approximately 32 fully matching, plus 344 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    list.The list focuses on the treatment and possible cure for chronic, progressive and often debilitating diseases and conditions, including breast cancer, multiple sclerosis (MS), type 2 diabetes, haemophilia and migraine.

  • Case study: OptiMiSe for MS nurses Case study: OptiMiSe for MS nurses

    Timescale:N/A. In the UK, MS services have been impacted by changing clinical and NHS landscapes. ... More than half of MSSNs based in the UK are engaged in OptiMiSe, impacting over 60, 000 patients with MS.

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Initially B-MS reported promising data for the combination therapy from a phase 3 trial called Checkpoint-227. ... B-MS withdrew its supplemental Biologics License Application (sBLA) in January this year, explaining that ‘further evidence on the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... The company says its latest trial results are the first and

  • Case study: The World vs MS Case study: The World vs MS

    Multiple sclerosis (MS) is an incurable neurological condition affecting over 2.5 million people around the world. ... solving to turn their minds to MS and offer solutions to the challenges posed.

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 49 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics